Valneva SE (VALN) Bundle
An Overview of Valneva SE (VALN)
General Summary of Valneva SE (VALN)
Valneva SE is a vaccine biotechnology company headquartered in Lyon, France, and Vienna, Austria. The company specializes in developing, manufacturing, and commercializing innovative vaccines.
| Company Details | Information |
|---|---|
| Headquarters | Lyon, France and Vienna, Austria |
| Founded | 2013 |
| Stock Exchange Listing | Euronext Paris |
Key products include:
- IXCHIQ™ (Chikungunya vaccine)
- VLA15 (Lyme disease vaccine)
- COVID-19 vaccine (discontinued in 2022)
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €388.4 million |
| Net Income | €95.5 million |
| Research & Development Expenses | €89.3 million |
Revenue Breakdown:
- IXCHIQ™ sales: €13.8 million
- Government contract revenues: €374.6 million
Industry Leadership
Valneva SE is recognized as a significant player in vaccine development, particularly in niche infectious disease markets.
| Key Competitive Advantages | Details |
|---|---|
| Vaccine Pipeline | 6 vaccines in development |
| Global Presence | Operations in Europe and North America |
| Strategic Partnerships | Collaborations with Pfizer, GSK |
Mission Statement of Valneva SE (VALN)
Mission Statement of Valneva SE (VALN)
Valneva SE's mission statement focuses on developing innovative vaccines targeting unmet medical needs in infectious diseases.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Vaccine Innovation | Developing novel vaccine technologies | 2 active vaccine development programs in 2024 |
| Infectious Disease Prevention | Targeting specific disease areas | Ongoing research in Lyme disease and COVID-19 vaccines |
| Global Health Impact | Addressing critical medical challenges | €295.4 million total revenue in 2022 |
Strategic Vaccine Development Priorities
- VLA15 Lyme disease vaccine clinical development
- COVID-19 vaccine research continuation
- Expansion of infectious disease portfolio
Research and Development Investment
Valneva invested €102.5 million in R&D expenses during the 2022 fiscal year, demonstrating commitment to vaccine innovation.
Current Vaccine Pipeline
| Vaccine | Development Stage | Target Disease |
|---|---|---|
| VLA15 | Phase 3 clinical trials | Lyme disease |
| COVID-19 vaccine | Discontinued | SARS-CoV-2 |
Geographic Market Focus
- European market primary region
- United States expansion strategy
- Global infectious disease targeting
Valneva maintains a strategic focus on developing vaccines for complex infectious diseases with significant unmet medical needs.
Vision Statement of Valneva SE (VALN)
Vision Statement of Valneva SE (VALN)
Strategic Global Vaccine Development FocusValneva SE aims to become a specialized vaccine company with a targeted global approach in vaccine development and commercialization.
| Vaccine Development Areas | Current Focus |
|---|---|
| Infectious Diseases | Chikungunya, Lyme disease, COVID-19 |
| Geographical Markets | Europe, United States |
| Research Investment (2023) | €53.1 million |
- Develop innovative vaccine technologies
- Create targeted immunization solutions
- Address unmet medical needs
Valneva targets niche vaccine markets with high unmet medical requirements and significant commercial potential.
| Market Segment | Strategic Approach |
|---|---|
| Rare Infectious Diseases | Specialized vaccine development |
| Geographic Coverage | Primarily European and North American markets |
As of 2024, Valneva maintains an active vaccine development pipeline across multiple disease areas.
| Vaccine Candidate | Development Stage | Target Disease |
|---|---|---|
| VLA15 | Phase 3 Clinical Trials | Lyme Disease |
| VLA1553 | FDA Approved | Chikungunya |
Valneva demonstrates significant investment in research and development to support its vision.
| Financial Metric | 2023 Value |
|---|---|
| R&D Expenses | €53.1 million |
| Total Revenue | €110.6 million |
Core Values of Valneva SE (VALN)
Core Values of Valneva SE (VALN) in 2024
Innovation and Scientific Excellence
Valneva SE demonstrates commitment to innovation through specific research and development efforts:
| R&D Investment | 2024 Budget |
|---|---|
| Total R&D Expenditure | €45.2 million |
| Vaccine Development Programs | 3 active clinical stage programs |
Patient-Centered Approach
Valneva focuses on critical vaccine development strategies:
- Lyme disease vaccine development (VLA15)
- COVID-19 vaccine collaboration efforts
- Pediatric vaccine portfolio expansion
Global Health Commitment
International vaccine development metrics:
| Geographic Reach | 2024 Statistics |
|---|---|
| Countries with Active Programs | 7 countries |
| Global Clinical Trial Sites | 12 active sites |
Sustainability and Ethical Practices
Environmental and corporate responsibility indicators:
- Carbon emission reduction target: 15% by 2025
- Ethical sourcing compliance: 100% verified suppliers
- Diversity in leadership: 35% female representation
Collaborative Research Approach
Research partnership details:
| Partnership Type | 2024 Collaboration Count |
|---|---|
| Academic Partnerships | 6 active collaborations |
| Pharmaceutical Collaborations | 4 strategic partnerships |
Valneva SE (VALN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.